Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.

Cheng AS, Leung SCY, Gao D, Burugu S, Anurag M, Ellis MJ, Nielsen TO.

Breast Cancer Res Treat. 2019 Sep 14. doi: 10.1007/s10549-019-05438-y. [Epub ahead of print]

PMID:
31522348
2.

Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically.

Chafe SC, McDonald PC, Saberi S, Nemirovsky O, Venkateswaran G, Burugu S, Gao D, Delaidelli A, Kyle AH, Baker JHE, Gillespie JA, Bashashati A, Minchinton AI, Zhou Y, Shah SP, Dedhar S.

Cancer Immunol Res. 2019 Jul;7(7):1064-1078. doi: 10.1158/2326-6066.CIR-18-0657. Epub 2019 May 14.

PMID:
31088846
3.

Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.

Asleh K, Lyck Carstensen S, Tykjaer Jørgensen CL, Burugu S, Gao D, Won JR, Jensen MB, Balslev E, Laenkholm AV, Nielsen DL, Ejlertsen B, Nielsen TO.

Int J Cancer. 2019 May 15;144(10):2578-2586. doi: 10.1002/ijc.31969. Epub 2018 Dec 6.

PMID:
30411790
4.

TIM-3 expression in breast cancer.

Burugu S, Gao D, Leung S, Chia SK, Nielsen TO.

Oncoimmunology. 2018 Aug 23;7(11):e1502128. doi: 10.1080/2162402X.2018.1502128. eCollection 2018.

5.

LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.

Burugu S, Gao D, Leung S, Chia SK, Nielsen TO.

Ann Oncol. 2017 Dec 1;28(12):2977-2984. doi: 10.1093/annonc/mdx557.

PMID:
29045526
6.

Emerging targets in cancer immunotherapy.

Burugu S, Dancsok AR, Nielsen TO.

Semin Cancer Biol. 2018 Oct;52(Pt 2):39-52. doi: 10.1016/j.semcancer.2017.10.001. Epub 2017 Oct 5. Review.

PMID:
28987965
7.

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO.

JAMA Oncol. 2017 Nov 9;3(11):e172085. doi: 10.1001/jamaoncol.2017.2085. Epub 2017 Nov 9.

8.

High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.

Nielsen TO, Jensen MB, Burugu S, Gao D, Jørgensen CL, Balslev E, Ejlertsen B.

Clin Cancer Res. 2017 Feb 15;23(4):946-953. doi: 10.1158/1078-0432.CCR-16-1278. Epub 2016 Sep 6.

9.

Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.

Burugu S, Asleh-Aburaya K, Nielsen TO.

Breast Cancer. 2017 Jan;24(1):3-15. doi: 10.1007/s12282-016-0698-z. Epub 2016 May 2. Review.

PMID:
27138387
10.

Efficient Strategy for the Construction of Both Enantiomers of the Octahydropyrroloquinolinone Ring System: Total Synthesis of (+)-Aspidospermidine.

Pandey G, Burugu SK, Singh P.

Org Lett. 2016 Apr 1;18(7):1558-61. doi: 10.1021/acs.orglett.6b00374. Epub 2016 Mar 21.

PMID:
26999058
11.

Prediction of preeclampsia-bench to bedside.

Acharya A, Brima W, Burugu S, Rege T.

Curr Hypertens Rep. 2014 Nov;16(11):491. doi: 10.1007/s11906-014-0491-3. Review.

PMID:
25239543
12.

HIV-1 translation and its regulation by cellular factors PKR and PACT.

Burugu S, Daher A, Meurs EF, Gatignol A.

Virus Res. 2014 Nov 26;193:65-77. doi: 10.1016/j.virusres.2014.07.014. Epub 2014 Jul 23. Review.

PMID:
25064266
13.

The PKR activator, PACT, becomes a PKR inhibitor during HIV-1 replication.

Clerzius G, Shaw E, Daher A, Burugu S, Gélinas JF, Ear T, Sinck L, Routy JP, Mouland AJ, Patel RC, Gatignol A.

Retrovirology. 2013 Sep 11;10:96. doi: 10.1186/1742-4690-10-96.

Supplemental Content

Loading ...
Support Center